Arrowhead Pharmaceuticals...

12.77
-1.05 (-7.60%)
At close: Mar 31, 2025, 2:31 PM

Arrowhead Pharmaceuticals Statistics

Share Statistics

Arrowhead Pharmaceuticals has 137.32M shares outstanding. The number of shares has increased by 0.43% in one year.

Shares Outstanding 137.32M
Shares Change (YoY) 0.43%
Shares Change (QoQ) 0.1%
Owned by Institutions (%) 79.93%
Shares Floating 114.16M
Failed to Deliver (FTD) Shares 110
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 9.45M, so 7.59% of the outstanding shares have been sold short.

Short Interest 9.45M
Short % of Shares Out 7.59%
Short % of Float 8.15%
Short Ratio (days to cover) 8.94

Valuation Ratios

The PE ratio is -3.87 and the forward PE ratio is -5.03. Arrowhead Pharmaceuticals's PEG ratio is -0.02.

PE Ratio -3.87
Forward PE -5.03
PS Ratio 653.4
Forward PS 2.7
PB Ratio 12.51
P/FCF Ratio -3.84
PEG Ratio -0.02
Financial Ratio History

Enterprise Valuation

Arrowhead Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.87B.

EV / Earnings -4.79
EV / Sales 808.97
EV / EBITDA -5.12
EV / EBIT -4.78
EV / FCF -4.75

Financial Position

The company has a current ratio of 6.74, with a Debt / Equity ratio of 2.75.

Current Ratio 6.74
Quick Ratio 6.74
Debt / Equity 2.75
Total Debt / Capitalization 73.36
Cash Flow / Debt -0.91
Interest Coverage -18.58

Financial Efficiency

Return on equity (ROE) is -3.23% and return on capital (ROIC) is -85.28%.

Return on Equity (ROE) -3.23%
Return on Assets (ROA) -0.53%
Return on Capital (ROIC) -85.28%
Revenue Per Employee $5,830.87
Profits Per Employee $-984,389.16
Employee Count 609
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax -2.77M
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -51.75% in the last 52 weeks. The beta is 0.92, so Arrowhead Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.92
52-Week Price Change -51.75%
50-Day Moving Average 18.11
200-Day Moving Average 21.46
Relative Strength Index (RSI) 31.8
Average Volume (20 Days) 1.89M

Income Statement

In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M and earned -599.49M in profits. Earnings per share was -5.

Revenue 3.55M
Gross Profit 3.55M
Operating Income -601.08M
Net Income -599.49M
EBITDA -561.51M
EBIT -601.08M
Earnings Per Share (EPS) -5
Full Income Statement

Balance Sheet

The company has 102.69M in cash and 510.55M in debt, giving a net cash position of -407.87M.

Cash & Cash Equivalents 102.69M
Total Debt 510.55M
Net Cash -407.87M
Retained Earnings -1.63B
Total Assets 1.01B
Working Capital 476.78M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -462.85M and capital expenditures -141.47M, giving a free cash flow of -604.32M.

Operating Cash Flow -462.85M
Capital Expenditures -141.47M
Free Cash Flow -604.32M
FCF Per Share -5.05
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -16.93K% and -16.88K%.

Gross Margin 100%
Operating Margin -16.93K%
Pretax Margin -17.25K%
Profit Margin -16.88K%
EBITDA Margin -15.81K%
EBIT Margin -16.93K%
FCF Margin -17.02K%

Dividends & Yields

ARWR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -36.23%
FCF Yield -31.89%
Dividend Details

Analyst Forecast

The average price target for ARWR is $34.5, which is 150% higher than the current price. The consensus rating is "Buy".

Price Target $34.5
Price Target Difference 150%
Analyst Consensus Buy
Analyst Count 10
Stock Forecasts

Stock Splits

The last stock split was on Nov 17, 2011. It was a backward split with a ratio of 1:10.

Last Split Date Nov 17, 2011
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -2.68
Piotroski F-Score 3